-
公开(公告)号：US20090162940A1
公开(公告)日：2009-06-25
申请号：US11569640
申请日：2005-05-17
CPC分类号： B01L3/5021 , A61B5/150022 , A61B5/150213 , A61B5/150343 , A61B5/150351 , A61B5/150755 , B01L2300/0838 , B01L2400/0406 , Y10T436/2575
摘要： A method and apparatus for analyzing a fluid sample. More particularly, this relates to a specimen analysis tube (2) for containing the specimen (12) sample and to a method of drawing the specimen sample (12) into the tube (2) by capillary action. When the sample (12) is drawn into the tube (2), air is expelled from the tube (2) in the direction which is counter to the flow of the sample (12) into the tube (2). The tube (2) can be U-shaped or it can be linear and can be disposed in a closed-ended holder (22) that is operative to vent air from the tube (2) in a direction which is counter to the direction of flow of the sample into the tube (2).
摘要翻译： 一种用于分析流体样品的方法和装置。 更具体地，涉及用于容纳样本（12）样本的样本分析管（2）和通过毛细管作用将样本样品（12）拉入管（2）的方法。 当样品（12）被吸入管（2）中时，空气从与样品（12）的流动相反的方向从管（2）排出到管（2）中。 管（2）可以是U形的，或者它可以是线性的，并且可以设置在闭合端的保持器（22）中，该保持器可操作以沿着与管（2）的方向相反的方向从管（2）排出空气 样品流入管（2）。
-
12.发明授权Method and apparatus for detecting insoluable constituents in a quiescent urine sample 有权用于检测静止尿样中不可溶成分的方法和装置公开(公告)号：US06448088B1
公开(公告)日：2002-09-10
申请号：US09317818
申请日：1999-05-25
IPC分类号： G01N2101
CPC分类号： G01N33/523 , B01L3/5027 , B01L3/50273 , B01L2300/0663 , B01L2300/0816 , B01L2300/0864 , B01L2300/0887 , B01L2400/0481 , B01L2400/0611 , G01N33/493 , G01N33/5002 , Y10S436/808 , Y10S436/809 , Y10T436/25125 , Y10T436/25375
摘要： A urine sample is analyzed for urine chemistry, formed bodies, and rare event evidence, all in a single sample container and under low power magnification. The sample container includes a urine sample receiving chamber which is connected to a urine chemistry chamber, to a formed body isolation chamber, and to a rare events detection chamber, so that the urine can flow from the receiving chamber to the other three chambers. The scanning instrument will scan the isolation chamber and can identify formed bodies by their characteristic light wave emission properties which result from the formed bodies exposure to the stains. The formed bodies can also be morphologically examined in the isolation chamber. The rare event detection chamber will include a component which will absorb essentially all of the water in the urine thus concentrating formed bodies on a surface in the chamber. This chamber can also be provided with one or more stains which will differentially highlight any rare events noted in the chamber by the scanning instrument. Rare events such as casts can be detected in this chamber.
摘要翻译： 分析尿液样品的尿液化学成分，成形体和罕见的事件证据，全部在单个样品容器中，在低功率放大下。 样品容器包括尿液接收室，尿液接收室连接到尿化学室，形成体隔离室，并且与稀有事件检测室相连，使得尿液可以从接收室流到另外的三个室。 扫描仪器将扫描隔离室，并且可以通过其形成的物体暴露于污渍产生的特征性光波发射特性来识别成形体。 成型体也可以在隔离室中进行形态学检查。 罕见事件检测室将包括将吸收尿液中基本上所有的水的成分，从而将成形体集中在腔室的表面上。 该室还可以具有一个或多个污渍，其将通过扫描仪器差异地突出腔室中注明的罕见事件。 在这个房间里可以检测到诸如铸件的罕见事件。
-
公开(公告)号：US5705739A
公开(公告)日：1998-01-06
申请号：US703509
申请日：1996-08-27
CPC分类号： G01N15/042 , G01N33/491 , Y10T436/25375
摘要： In most mammals studied, a histogram of the erythrocytes' density of a healthy individual normally has a Gaussian distribution. Gaussian or near-Gaussian distributions may be characterized by their mean, by their standard deviation, and their absence of skewness. A measurement of the erythrocyte density distribution (EDD) in mammalian whole blood which has been anticoagulated with heparin can yield information which is indicative of certain physiologic and pathophysiologic conditions that are characterized by various EDD abnormalities. These abnormalities may include abnormalities in the standard deviation of the EDD; the mean erythrocyte density; and any skewness of the EDD curve. The hematocrit or percent packed red cell volume, which is obtained at the same time as the EDD can also yield information. The EDD measurement is made by providing a sample of heparin anticoagulated whole mammalian blood to which is added a plurality of density markers having known individual specific gravities that are within the range of specific gravity values of mammalian erythrocytes. The blood sample-density marker mixture is centrifuged, and measurements are taken of the location of the density markers within the centrifuged erythrocyte cell pack. These measurements are analyzed to determine the standard deviation of the EDD in the sample; the mean erythrocyte density in the sample; the hematocrit value of the sample; and any skewness in the EDD curve in the sample. The resultant data is compared to empirical data obtained from patient populations with known normal and abnormal medical histories in order to determine whether there is any variation from norm of one or more of the parameters measured which are characteristic of abnormal medical conditions. Alternatively since an erythrocyte's hemoglobin concentration (HC) is the main determinant of an ethrocyte's density, HC measured on a cell counter that determines each erythrocyte's HC may be used as a surrogate for erythrocyte density. Suitable cell counters can also derive HCT from a blood sample.
-
公开(公告)号：US5635362A
公开(公告)日：1997-06-03
申请号：US247336
申请日：1994-05-23
申请人： Robert A. Levine , Stephen C. Wardlaw , Rodolfo R. Rodriguez , Adrien P. Malick , Alvydas J. Ozinskas
发明人： Robert A. Levine , Stephen C. Wardlaw , Rodolfo R. Rodriguez , Adrien P. Malick , Alvydas J. Ozinskas
IPC分类号： G01N33/543 , B01L3/14 , G01N33/49 , G01N33/537 , G01N33/569 , G01N33/58 , G01N33/558
CPC分类号： B01L3/5021 , G01N33/491 , G01N33/5375 , G01N33/56972 , G01N33/585 , Y10S435/81 , Y10S435/967 , Y10S435/971 , Y10S435/973 , Y10S436/805 , Y10S436/81 , Y10S436/824 , Y10S436/829 , Y10T436/111666
摘要： A patient's health may be diagnosed by centrifuging blood samples in a transparent tube, which tube contains one or more bodies or groups of bodies such as floats, inserts, liposomes, or plastic beads of different densities. Each density-defined body carries analyte-capture binding materials such as antigens or antibodies, which are specific to an epitope, or other specific high affinity binding site on a target analyte which target analyte may be in the blood or other sample being tested; and the level of which analyte is indicative of the patient's health. At least one labeled binding material which is also specific to an epitope, or other specific high affinity binding site on the target analyte is added to the sample so as to form labeled binding material/analyte/body complexes in the sample. Upon centrifugation, the complexes will settle out in different areas in the tube according to the respective density of the body or bodies; and the degree of label emission of the complex layers can enable qualitative and/or quantitative analyses of the sample to be made. Unbound labeled binding materials will be separated from the complexed layers by the washing action of ascending or descending components of the sample during the centrifugation step. Unbound labeled binding material will thus not interfere with the analysis.
摘要翻译： 可以通过将透明管中的血液样品离心来诊断患者的健康，该管包含一个或多个不同密度的浮体，插入物，脂质体或塑料珠的主体或组。 每个密度定义的身体携带分析物 - 捕获结合材料，例如抗原或抗体，其对靶分析物是特异性的，或靶分析物上的其它特异性高亲和力结合位点，其目标分析物可能在待测试的血液或其他样品中; 并且其分析物的水平表示患者的健康。 将至少一种对靶分析物上的表位或其他特异性高亲和力结合位点特异性的标记结合物质加入到样品中，以便在样品中形成标记的结合材料/分析物/身体复合物。 离心后，复合物将根据身体或身体的相应密度沉淀在管中的不同区域; 并且复合层的标签发射程度可以使得要进行样品的定性和/或定量分析。 通过在离心步骤期间样品的上升或下降组分的洗涤作用，未结合的标记结合材料将从复合层分离。 因此，未结合的标签结合材料不会影响分析。
-
公开(公告)号：US5460979A
公开(公告)日：1995-10-24
申请号：US192629
申请日：1994-02-07
申请人： Robert A. Levine , Stephen C. Wardlaw , Leon W. M. M. Terstappen , Thomas J. Mercolino , Diether J. Recktenwald
发明人： Robert A. Levine , Stephen C. Wardlaw , Leon W. M. M. Terstappen , Thomas J. Mercolino , Diether J. Recktenwald
IPC分类号： G01N33/543 , B01L3/14 , G01N33/49 , G01N33/537 , G01N33/569 , G01N33/58 , G01N33/538 , G01N33/546
CPC分类号： B01L3/5021 , G01N33/491 , G01N33/5375 , G01N33/56972 , G01N33/585 , Y10S435/81 , Y10S435/967 , Y10S435/971 , Y10S435/973 , Y10S436/805 , Y10S436/81 , Y10S436/824 , Y10S436/829 , Y10T436/111666
摘要： A patient's health is diagnosed by centrifuging blood samples in a transparent tube, which tube contains one or more groups of particles such as lyposomes or plastic beads of different densities for each group. Each group of density-defined particles carries antigens or antibodies which are specific to a complement antigen or antibody which may be in the blood sample being tested, and which are indicative of the patient's health. A label-tagged antibody which is specific to all bound antibody/antigen couples is added to the blood sample so as to form labelled antibody+antigen-antibody complexes (AAAC) in the blood sample. Upon centrifugation, the complexed particles will settle out in different areas in the tube according to the respective density of the particles, and the degree of label emission of the particle layers can enable qualitative or quantitative analyses of the blood sample to be made. Unbound labelled antibodies will be washed away from the complexed layers by the washing action of the descending blood cells during the centrifugation step. Unbound labelled antibodies will thus not interfere with the analysis.
摘要翻译： 通过在透明管中离心血液样品来诊断患者的健康，该管含有一组或多组颗粒，例如每组的不同密度的溶血细胞或塑料珠。 每组密度定义的颗粒携带对可能在被测试的血液样品中的补体抗原或抗体特异性的抗原或抗体，并且其表示患者的健康。 向血液样品中加入对所有结合的抗体/抗原对特异性的标记标签抗体，以在血液样品中形成标记抗体+抗原 - 抗体复合物（AAAC）。 离心后，根据颗粒的相应密度，络合的颗粒将沉淀在管中的不同区域中，并且颗粒层的标签发射程度可以使得要进行血液样品的定性或定量分析。 在离心步骤中，未结合的标记抗体将通过下降血细胞的洗涤作用从复合层中洗去。 因此，未结合的标记抗体不会干扰分析。
-
公开(公告)号：US5331973A
公开(公告)日：1994-07-26
申请号：US31533
申请日：1993-03-15
IPC分类号： A61B10/00 , G01N33/483 , A61B5/00
CPC分类号： A61B10/0038
摘要： The specification discloses a method for enhancing the reliability of screening tests used for detecting the presence or absence of chemical markers associated with gastrointestinal cancer. The method comprises the steps of providing a laxative purge for administration to a patient, collecting a watery fecal sample and then applying the watery fecal sample to a test medium having an indicator to indicate the presence of chemical markers associated with gastrointestinal cancer, if there. Two alternative methods are suggested for obtaining a watery fecal sample. In a first embodiment, the purge is administered to the patient following a recent bowel movement and the first watery post-purge bowel movement is collected. In a second embodiment, the purge is administered to the patient, the first post-purge bowel movement is discarded and the second watery post-purge bowel movement is collected.
摘要翻译： 该说明书公开了一种用于增强用于检测与胃肠癌相关的化学标记物的存在或不存在的筛选试验的可靠性的方法。 该方法包括以下步骤：向患者提供泻药吹扫，收集水样粪便样品，然后将含水粪便样品施用于具有指示剂的测试培养基，以指示与胃肠癌相关的化学标记的存在（如果有的话）。 建议采用两种替代方法来获得水样粪便样品。 在第一实施例中，在最近的肠运动之后向患者施用吹扫，并且收集第一次含水的后清除肠运动。 在第二实施例中，向患者施用吹扫，弃去第一次清除后肠道运动，并收集第二次含水的清洗后肠道运动。
-
17.发明授权
公开(公告)号：US5171528A
公开(公告)日：1992-12-15
申请号：US740289
申请日：1991-08-05
IPC分类号： G01N33/72
CPC分类号： G01N33/725 , G01N33/726 , Y10S435/805 , Y10T436/255
摘要： The specification discloses a fecal occult blood test device capable of determining whether the blood found during the test originated in the upper or lower gastrointestinal track. A fecal sample is applied to a test medium charged to be differentially attractive to blood components originating in the upper and lower gastrointestinal track respectively. A solvent is applied to the test specimen to cause differential migration of the blood components and an indicator is then applied to indicate the presence of the blood components, if any.
摘要翻译： 本说明书公开了一种能够确定测试期间发现的血液是否起源于上胃肠道或下胃肠道的粪便潜血检测装置。 将粪便样品应用于分别对源自上胃肠道和下胃肠道的血液成分具有差异吸引力的测试介质。 将溶剂施加到测试样品上以引起血液成分的差异迁移，然后施加指示剂以指示血液成分的存在（如果有的话）。
-
公开(公告)号：US4808379A
公开(公告)日：1989-02-28
申请号：US699748
申请日：1985-02-08
CPC分类号： G01N33/726 , A61B10/0038 , Y10S435/805
摘要： The device is used in the same way as toilet tissue to obtain a stool sample for occult blood testing on a receptor sheet included in the device. The receptor sheet is preimpregnated with guaiac or other suitable reagent. A performance/control monitor is included in the device and is kept separated and spaced apart from the receptor sheet until after the stool sample is obtained. Once the stool sample is obtained, the performance/control monitor is brought into and retained in face-to-face contact with the receptor sheet. Upon return to the physician, the developer reagent is applied to the receptor sheet in the area of the stool and in the area of the monitor. Maintaining the monitor out of contact with the receptor sheet until the stool sample is taken prevents the occurrence of a false positive monitor reaction, which can happen when there is extended contact between the monitor and the reagent impregnated receptor sheet.
摘要翻译： 该装置以与卫生纸相同的方式使用，以获得用于在装置中包括的受体片上进行隐血测试的粪便样品。 受体片用愈创木酚或其它合适的试剂进行预浸渍。 设备中包括性能/控制监视器，并且与受体片材保持分离并间隔开直到获得粪便样品。 一旦获得粪便样品，就将性能/控制监视器与受体片面对面接触并保持。 返回医生后，将显影剂试剂施用于粪便区域和监护仪区域中的受体片。 保持显示器不与受体片接触直到取出粪便样本，以防止在显示器与试剂浸渍的接收片之间发生延长的接触时发生假阳性监测反应。
-
公开(公告)号：US4774965A
公开(公告)日：1988-10-04
申请号：US68572
申请日：1987-07-01
申请人： Rodolfo R. Rodriguez , Matthew W. Lesnieskl , Charles F. Galanaugh , Robert A. Levine , Stephen C. Wardlaw , Theodore Juraschek
发明人： Rodolfo R. Rodriguez , Matthew W. Lesnieskl , Charles F. Galanaugh , Robert A. Levine , Stephen C. Wardlaw , Theodore Juraschek
CPC分类号： B01L3/50215 , G01N15/05
摘要： A centrifuge tube is used to hold a mixture of several constituents, and also contains a generally cylindrical float. The float settles, after centrifugation, into the zone occupied by the constituent whose volume is to be measured. The constituent layer will settle, after centrifugation, into the annular space between the tube bore and the outside of the float, and will be expanded axially due to the restricted volume of the annular space. The degree of expansion is dependent upon the respective sizes of the float O.D. and the tube bore ID, both of which must be closely controlled for accurate results. A known volume of a control material is placed in the tube to settle into the annular space during centrifugation in an area thereof outside of the constituent layer zone. The length of the band of the control material is measured after centrifugation and is compared to a known length which will result if the annular space is of the proper target volume. A correction factor is thus obtained and applied to all of the other constituent layers which were measured. The band thus forms a varying reference which reflects the actual volume of the annulus.
-
公开(公告)号：US4700715A
公开(公告)日：1987-10-20
申请号：US324073
申请日：1981-11-23
CPC分类号： A61B5/4393
摘要： A device which is circumferentially affixed to a flaccid penis about the proximal portion of the shaft thereof prior to retiring at night. The device is in the form of a band of material which includes an expandable portion which will not retract once expanded. In the event of a nocturnal erection, the device will expand in response to circumferential enlargement of the penis which occurs during the erection. The expanded device is retrieved upon arising in the morning and is dispatched to one's physician for analysis.
摘要翻译： 在晚上退休之前，周围地将其附着于松弛的阴茎周围的器具的轴的近端部分。 该装置是一种材料带的形式，其包括可膨胀部分，该可膨胀部分一旦膨胀就不会缩回。 在夜间勃起的情况下，装置将响应于在勃起期间发生的阴茎的周向扩大而膨胀。 扩大的装置在早晨出现时被检索，并被派往医生进行分析。
-
-
-
-
-
-
-
-
-
搜索结果
209 条记录 (耗时 0.041 秒)
